These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11451318)

  • 1. Cohort study of metastatic melanoma patients in the Dermatology Institute of Florence 1990/1997.
    Moretti S; Carli P; Biggeri A; Volpi V; Pimpinelli N
    J Eur Acad Dermatol Venereol; 2001 Jan; 15(1):30-3. PubMed ID: 11451318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma.
    Young AM; Marsden J; Goodman A; Burton A; Dunn JA
    Clin Oncol (R Coll Radiol); 2001; 13(6):458-65. PubMed ID: 11824887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z; Strojan P
    Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete responses and survival after polychemotherapy plus interferon-alpha for patients with metastatic melanoma.
    Vuoristo MS
    Melanoma Res; 1996 Aug; 6(4):331-6. PubMed ID: 8873054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
    Strojan P; Rudolf Z
    Melanoma Res; 1997 Oct; 7(5):420-7. PubMed ID: 9429226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
    Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
    Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
    Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
    Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
    J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
    Huncharek M; Caubet JF; McGarry R
    Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
    Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
    J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.
    Hersey P; McLeod GR; Thomson DB
    Br J Haematol; 1991 Oct; 79 Suppl 1():60-6. PubMed ID: 1931712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
    Van Dyk JJ; Falkson G
    Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects.
    Keilholz U; Scheibenbogen C; Möhler T; Brossart P; Maclachlan D; Geueke AM; Jochim A; Hunstein W
    Melanoma Res; 1995 Aug; 5(4):283-7. PubMed ID: 7496166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
    Andersson R; Ake Hofer P; Riklund-Ahlström K; Henriksson R
    Melanoma Res; 2003 Feb; 13(1):87-91. PubMed ID: 12569290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations.
    Betticher DC; Lee SM; Morris C; Clemons M; Thatcher N
    Melanoma Res; 1995 Aug; 5(4):277-82. PubMed ID: 7496165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.